Literature DB >> 1469954

Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients.

I T Houghton1, K Chan, Y C Wong, C S Aun, O W Lau, D M Lowe.   

Abstract

The pharmacokinetics of pethidine after a single intramuscular injection were studied in 30 male patients of Caucasian, Chinese and Nepalese extraction. There were no significant differences between the three ethnic groups in the mean time for maximum absorption (tmax) and peak plasma concentration (Cmax) of pethidine. The mean (+/- S.D.) elimination half life (t1/2) of pethidine was shorter in Caucasians (4.5 +/- 1.3 h) compared with Nepalese (6.3 +/- 1.6 h) and Chinese (8.1 +/- 3.1 h) (p < 0.01). The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients). No apparent ethnic differences were found in the tmax and Cmax of norpethidine which emerged as the major metabolite in the plasma in the three races. An apparently higher area under plasma concentration-time curve (AUC infinity [symbol: see text]) and longer elimination t1/2 of the metabolite were observed in the two Asian patient groups. It appears that both the Chinese and Indian groups did not eliminate pethidine as effectively as the Caucasians after a single intramuscular injection, which may be the result of interethnic variability in the metabolism of pethidine. Caution may be required on multiple dosing of pethidine in Asian patients due to the possible accumulation of the parent drug and its toxic metabolite, norpethidine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469954

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  4 in total

Review 1.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

3.  Biotransformation of pethidine: a comparative study of 24 h urine in three ethnic groups.

Authors:  I T Houghton; K Chan; Y C Wong; D H Leung; C S Aun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

4.  The Fear of Pain Questionnaire-III and the Fear of Pain Questionnaire-Short Form: a confirmatory factor analysis.

Authors:  Sara M Vambheim; Peter Solvoll Lyby; Per M Aslaksen; Magne Arve Flaten; Ole Åsli; Laila M Martinussen
Journal:  J Pain Res       Date:  2017-08-08       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.